ArticleThe Journal of allergy and clinical immunology2025
Human airway epithelial B-cell activating factor is reduced in early life but is virally induced via JAK/STAT.
Article in The Journal of allergy and clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Increased respiratory pathogen positivity and diversity in hospitalized children following the COVID-19 pandemic in Malaysia.New microbes and new infections · 2026Article
- BAFF as a Key Modulator of Respiratory Mucosal B Cell Immunity in Viral Infection and Mucosal Vaccination.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEarly infancy is marked by high susceptibility to severe viral respiratory infections and reduced protective antibody responses, making rapid development of local airway immunity essential. Despite this, the developmental dynamics of human airway B cells and their interaction with airway epithelial cells (AECs) in early life remain poorly understood.
objectiveWe studied the developmental dynamics of human airway B-cell populations, the variation in AEC-derived B-cell survival and maturation factors with age, and how viral respiratory infections influence their production.
methodsChanges in human airway B-cell populations and survival receptors across different pediatric age groups were analyzed by using a single-cell RNA sequencing dataset. The production of B-cell activating factor (BAFF) and other B-cell survival and maturation factors by human AECs was assessed in infants (<12 months) and older children, both at baseline and after viral stimulation in vitro. Additional in vivo validation studies assessed airway BAFF production at baseline and during PCR-confirmed viral respiratory infections across pediatric age groups.
resultsWe observed age-dependent shifts in airway B-cell composition, identifying the BAFF/BAFF-receptor axis as critical for B-cell maturation and survival in early life. Although BAFF production in AECs is initially reduced in infants (<12 months), it can be activated by viral stimuli both in vivo and in vitro. Mechanistic studies showed that BAFF production in human infant AECs is induced by type I and III interferons via JAK/STAT signaling.
conclusionHuman AEC JAK/STAT signaling activation regulates the early maturation of airway B-cell responses via local BAFF induction, particularly during viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.